Research programme: epigallocatechin gallate-based anticancer therapeutics - Viteava Pharmaceuticals

Drug Profile

Research programme: epigallocatechin gallate-based anticancer therapeutics - Viteava Pharmaceuticals

Alternative Names: EGCG-based anticancer therapeutics - Viteava; Green tea flavonoid-based anticancer therapeutics - Viteava; Proteasome endopeptidase complex inhibtors - Viteava; VEA-005; VEA-006; VPE-001; VPEA-002; VPEA-004

Latest Information Update: 31 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator H. Lee Moffitt Cancer Center and Research Institute; Hong Kong Polytechnic University; McGill University; University of South Florida; Wayne State University
  • Developer McGill University; Viteava Pharmaceuticals
  • Class Catechins; Flavonoids; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 31 Jan 2014 Epigallocatechin gallate-based anticancer therapeutics is available for licensing as of 31 Jan 2014.
  • 31 Jan 2014 Preclinical trials in Cancer in Canada (unspecified route)
  • 28 Jan 2014 Viteava Pharmaceuticals and McGill University enter into a sponsored research agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top